Introduction:
BiomeBank plans to open a new good manufacturing practise (GMP) facility to advance biomedical research and production in Adelaide, Australia.
Features:
The opening of its new GMP manufacturing facility marks a pivotal moment in bolstering the worldwide availability of their established donor-derived microbiome-based therapy. Moreover, this expansion is strategically aligned to propel the continued development and enhancement of their next-generation therapies.
The new facility in Adelaide's biomedical area is set up to help people work together and come up with new ideas in South Australia's growing medical field. Alongside the GMP facility for production, it will also include a brand-new research and development lab and office space.
The facility will aid in expanding the distribution of microbiome-based therapies to additional regions to address the increasing worldwide need. Additionally, the research and development lab will play a pivotal role in advancing pipeline of second-generation products.
This facility will enable the continued development and expansion of consortiome TM—a groundbreaking artificial cultured human microbiome produced within a bioreactor. This innovative technology holds promise in offering widespread replacement of human gut microbes at a scalable level, potentially addressing various common diseases.
The upcoming facility will increase its current staff from 18 to 32, and expect ongoing expansion throughout the year 2024.
Specifications:
Name BiomeBank
Type New Construction
